BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates

Company Performance - BioLife Solutions reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.14, and an improvement from a loss of $0.23 per share a year ago, representing an earnings surprise of 57.14% [1] - The company posted revenues of $28.33 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 19.03%, although this is a decline from year-ago revenues of $39.51 million [2] - Over the last four quarters, BioLife Solutions has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - BioLife Solutions shares have increased approximately 35.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.11 on revenues of $24.5 million, and for the current fiscal year, it is -$0.47 on revenues of $105.93 million [7] Industry Outlook - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]